NPS PHARMACEUTICALS INC 4
4 · NPS PHARMACEUTICALS INC · Filed Jan 9, 2014
Insider Transaction Report
Form 4
STRATEMEIER ED
SVP & Acting GC
Transactions
- Award
Stock Options
2014-01-07+6,750→ 39,375 totalExercise: $3.34Exp: 2020-02-19→ Common Stock (6,750 underlying)
Footnotes (1)
- [F1]On February 19, 2010, the Reporting Person was granted options to purchase shares of Common Stock under the Issuer's 2005 Omnibus Incentive Plan, which are subject to both performance conditions and time-based vesting. On January 7, 2014, the performance criteria for 6,750 of these options was satisfied when the FDA accepted the BLA for Natpara for the treatment of hypoparathyroidism. As of January 7, 2014, the performance criteria and the time-based criteria for 55,688 of these options has been satisfied. These options will vest and become exercisable based on the following vesting schedule: 25% on each of the first four anniversaries of the date of grant.